Document is current
Any future updates will be listed below
-
Authors
Ohtani, Seiya
Watanabe, Narumi
Ihara, Keiko
Takahashi, Nobuyuki
Miyazaki, Naoki
Ishizuchi, Kei
Takemura, Ryo
Hori, Satoko
Nakahara, Jin
Takizawa, Tsubasa
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science,Japan (JSPS KAKENHI (22K15693))
- License Information
-
More Information
Article History
Received: 6 July 2023
Accepted: 26 October 2023
First Online: 14 November 2023
Declarations
:
: This study was approved by Ethics Committee of the Keio University School of Medicine (approval number: 20211144). Patients were informed about this observational study via the institute’s website, and they could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine, in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: TT is a consultant/advisor and/or served as advisory board for Otsuka, Eli Lilly, Amgen, Pfizer and Teijin. TT received speaker honoraria from Otsuka, Eli Lilly, Daiichi Sankyo, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and research funding from Eli Lilly and Tsumura outside the submitted work. JN received honoraria and research scholarships from Amgen and Daiichi Sankyo. Other authors have nothing to disclose.
